Angewandte
Chemie
variant CNE1, with a resist-
ance factor of 1.2(IC
(CNE1)/IC50(SUNE1)
-
50
ratio) less than one third of
that observed for cisplatin
(3.9). The IC50 value of 3-Cl
for normal human cells
CCD-19Lu was determined
to be 19.1 mM, thus indicat-
ing that this AuI compound
is 2.3–2.9-fold less toxic to
normal cells than to the
forging cancer cells.
In summary, we have
observed a new coordina-
tion mode of the pyridyl-
2,6-diphenyl2À ligand and
isolated two AuI compounds
that contain unprecedented
types of gold metallamacro-
cycles. Both types of metal-
lamacrocycle have intramo-
À
Figure 3. Proposed conformational changes of 4 in solution viewed from the top (upper) and side (lower) of
the molecules. The structure of 5 was built using Chem3D 5.0 on the basis of the crystal structure of 4.
lecular AuI···AuI and
C
6
6
8
8
À
À
À
H
H ’, H H ’, and Ph Ph’ pairs (see Figure 3 and the
H···p interactions; the metallamacrocycle with stronger
I
I
À
Supporting Information), together with the cross signals that
possibly arise from the exchanges between 4 and 5, in
accordance with the conformational changes shown in
Figure 3. Notably, the H3, H4, and H3’ signals of 4 (d = 5.7–
6.3 ppm) are considerably upfield from the corresponding
signals of 3 (d ꢁ 6.9–7.1 ppm), which could result from
Au ···Au and C H···p interactions is highly robust in solution
and shows interesting topological and cytotoxic properties,
whereas the other exhibits a unique fluxional behavior in
solution. The present work demonstrates that polydentate
cyclometalating ligands, such as pyridyl-2,6-diaryl2À, together
with AuI could be useful for constructing new classes of
molecules with unprecedented topology and properties.
À
intramolecular C H···p interactions (see the Supporting
À
Information). Such C H···p interactions do not exist in 5,
Received: March 1, 2006
Published online: June 22, 2006
consistent with the downfield shift of these signals, partic-
ularly for H3, upon increasing temperature (which increases
the 5/4 molar ratio).
Keywords: aurophilicity · gold · metallacycles · Möbius strip ·
Complexes 3-Cl, 3-ClO4, and 3-PF6 are remarkably stable
both in organic solvents (such as CH2Cl2, CHCl3, dimethyl-
formamide (DMF), and dimethylsulfoxide (DMSO)) and
under physiologically relevant conditions (see the Supporting
Information). The high stability of 3-Cl in solution relative to
most self-assembled polynuclear AuI compounds, including 4
(which decomposed within several days in a solution of CHCl3
at room temperature), prompted us to examine its cytotoxic
properties; gold compounds not only have long been used as
antiarthritic drugs but also are promising antitumor agents,[16]
and stability is an important issue in the design of new AuI
therapeutic agents. The cytotoxicities of 3-Cl toward cancer
cell lines (including cervical epithelioid carcinoma (HeLa)
and nasopharyngeal carcinoma (SUNE1 and its cisplatin-
resistant variant CNE1)) and normal lung fibroblast cells
(CCD-19Lu) were determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. From
the cytotoxicity profiles (see the Supporting Information), the
corresponding IC50 values (dose required for the inhibition of
50% cellular growth) of the cancer cell lines were determined
to be 6.53–8.20 mM, which are comparable to those of the
clinically used cisplatin (IC50 = 14.8 (HeLa), 2.3 (SUNE1),
and 8.9 mM (CNE1)). Importantly, 3-Cl was found to be
almost equally cytotoxic to SUNE1 and its cisplatin-resistant
.
structure elucidation
[1] a) D. B. Amabilino, J. F. Stoddart, Chem. Rev. 1995, 95, 2 72 5;
b) C. Piguet, G. Bernardinelli, G. Hopfgartner, Chem. Rev. 1997,
97, 2005; c) F. M. Raymo, J. F. Stoddart, Chem. Rev. 1999, 99,
1643; d) S. Leininger, B. Olenyuk, P. J. Stang, Chem. Rev. 2000,
100, 853.
[2] H. S. Rzepa, Chem. Rev. 2005, 105, 3697.
[3] a) D. Ajami, O. Oeckler, A. Simon, R. Herges, Nature 2003, 426,
819; b) T. Kawase, M. Oda, Angew. Chem. 2004, 116, 4496;
Angew. Chem. Int. Ed. 2004, 43, 4396.
[4] O. Cador, D. Gatteschi, R. Sessoli, F. K. Larsen, J. Overgaard,
A.-L. Barra, S. J. Teat, G. A. Timco, R. E. P. Winpenny, Angew.
Chem. 2004, 116, 5308; Angew. Chem. Int. Ed. 2004, 43, 5196.
[5] D. M. Walba, R. M. Richards, R. C. Haltiwanger, J. Am. Chem.
Soc. 1982, 104, 3219.
[6] a) S. Tanda, T. Tsuneta, Y. Okajima, K. Inagaki, K. Yamaya, N.
Hatakenaka, Nature 2002, 417, 397; b) G. R. Patzke, Angew.
Chem. 2003, 115, 1002; Angew. Chem. Int. Ed. 2003, 42, 972.
[7] a) K.-H. Wong, K.-K. Cheung, M. C.-W. Chan, C.-M. Che,
Organometallics 1998, 17, 3505; b) C.-M. Che, C. K.-L. Li, R. W.-
Y. Sun, S. C.-F. Kui, N. Zhu, Chem. Eur. J., DOI: 10.1002/
chem.200600117.
[8] Prepared by treating 2,6-bis(2’-bromophenyl)pyridine with
nBuLi, followed by addition of TMEDA; see: S. C. F. Kui,
Angew. Chem. Int. Ed. 2006, 45, 4663 –4666
ꢀ 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim